Page 11 - Licensed Producers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Looking for deep value? Forget GameStop stock and consider Alimentation Couche-Tard Inc. (TSX:ATD.B) as it steathily enters pot retail.

Press Release – Greenlab Greenlab (Green Relief NZ Ltd trading as Greenlab) based at Lincoln University is positioning New Zealand at the forefront of research-driven pharmaceutical-quality cannabis cultivation and derivative products, is pleased to announce that its subsidiary, … Greenlab (Green Relief NZ Ltd trading as Greenlab) based at Lincoln University is positioning New Zealand at the forefront of research-driven pharmaceutical-quality cannabis cultivation and derivative products, is pleased to announce that its subsidiary, Greenlab Australia Pty Ltd, has entered into an agreemen...

Thursday, 4 February 2021, 6:47 am Greenlab (Green Relief NZ Ltd trading as Greenlab) based at Lincoln University is positioning New Zealand at the forefront of research-driven pharmaceutical-quality cannabis cultivation and derivative products, is pleased to announce that its subsidiary, Greenlab Australia Pty Ltd, has entered into an agreement to supply pharmaceutical-grade, cannabinoid pharmaceuticals to Cannvalate Pty Ltd, one of Australia’s largest distributors. Under the two-year agreement, Greenlab will supply a range of certified cannabis products that meet the high-quality standa...

With Fragmented Healthcare System, Primary Care Companies Are in Focus The multi-trillion-dollar U.S. healthcare market is ripe for disruption. After all, the current system is fragmented, meaning there exists a lack of coordination that often results in an inefficient allocation of resources. “Fragmentation adversely impacts quality, cost, and outcomes. Eliminating waste from unnecessary, unsafe care is crucial for improving quality and reducing costs-and making the system financially sustainable,” says The American Journal of Managed Care (AJMC). Making matters far worse, doctors often ...

Based on Positive Pre-IND Meeting With FDA, MindMed is Now Prepared to Open an Investigational New Drug (IND) in August 2021 With a Phase 2B Clinical Trial for LSD Assisted Therapy in Anxiety MindMed (OTCQB:MMEDF) announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. FDA regarding the development of LSD assisted therapy for an anxiety disorder. MindMed also provided a clinical development update on 18-MC announcing the firm continues to dose escalation of 18-MC in Phase I SAD/MAD and has confirmed a meeting with the FDA.